Flare-up reaction in the inoculation drug sites by glatiramer acetate: First case described

Flare-up reaction in the inoculation drug sites by glatiramer acetate: First case described

Bibliographic Details
Main Authors:	María-José Sánchez-González, José Barbarroja-Escudero, Darío Antolín-Amérigo, Mercedes Rodríguez-Rodríguez, Laura Pericet-Fernández, Dolores Vélez, Teresa Bellón-Heredia, Melchor Alvarez-Mon
Format:	Article
Language:	English
Published:	Elsevier 2016-10-01
Series:	Allergology International
Online Access:	http://www.sciencedirect.com/science/article/pii/S1323893016300260

Similar Items

Hypersensitivity reactions and drug fever by bendamustine: A case report of three patients
by: José Barbarroja-Escudero, et al.
Published: (2015-01-01)

Bleak allergy: First case report
by: José Barbarroja-Escudero, et al.
Published: (2016-10-01)

Diagnosis of IgE-mediated hypersensitivity to sesame seeds supplemented with lipid body proteins
by: José Barbarroja-Escudero, et al.
Published: (2015-10-01)

Pine Nut Anaphylaxis: A Proteomic Study
by: José Barbarroja-Escudero, et al.
Published: (2014-01-01)

Physicochemical and Biological Examination of Two Glatiramer Acetate Products
by: Arthur Komlosh, et al.
Published: (2019-07-01)

The role of glatiramer acetate in the early treatment of multiple sclerosis
by: David W Brandes
Published: (2010-06-01)

Glatiramer Acetate-associated Refractory Immune Thrombocytopenic Purpura
by: Iftach Sagy, et al.
Published: (2016-04-01)

Fixed drug urticaria: A report of two patients
by: José Barbarroja-Escudero, et al.
Published: (2015-01-01)

New features of glatiramer acetate for the treatment of remitting multiple sclerosis
by: N. Y. Lasch
Published: (2015-12-01)

The Novel Effect of Immunomodulator-Glatiramer Acetate on Epileptogenesis and Epileptic Seizures
by: Ming-Chi Lai, et al.
Published: (2018-10-01)

Embolia Cutis Medicamentosa after Subcutaneous Injection with Glatiramer Acetate
by: Lyubomira Vlahova, et al.
Published: (2021-02-01)

The influence of glatiramer acetate on Th17-immune response in multiple sclerosis.
by: Mikhail Melnikov, et al.
Published: (2020-01-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
by: Oscar Fernández
Published: (2012-08-01)

Clinical Utility of Glatiramer Acetate in the Management of Relapse Frequency in Multiple Sclerosis
by: Oscar Fernández
Published: (2012-04-01)

Comparing the biological impact of glatiramer acetate with the biological impact of a generic.
by: Fadi Towfic, et al.
Published: (2014-01-01)

Molecular Profiling of Glatiramer Acetate Early Treatment Effects in Multiple Sclerosis
by: Anat Achiron, et al.
Published: (2009-01-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Experience of Glatiramer Acetate in the Treatment of Relapsing-Remitting Multiple Sclerosis Patients
by: Özlem Taşkapılıoğlu, et al.
Published: (2012-03-01)

Two decades of subcutaneous glatiramer acetate injection: current role of the standard dose, and new high-dose low-frequency glatiramer acetate in relapsing–remitting multiple sclerosis treatment
by: Caporro M, et al.
Published: (2014-08-01)

Drug-Induced Liver Injury by Glatiramer Acetate Used for Treatment of Multiple Sclerosis
by: Attila Onmez, et al.
Published: (2013-12-01)

Liver injury and glatiramer acetate, an uncommon association: case report and literature review
by: Javier Almeida, et al.
Published: (2017-11-01)

CD8(+) T Cells Are Required For Glatiramer Acetate Therapy in Autoimmune Demyelinating Disease.
by: Andrew F Tyler, et al.
Published: (2013-01-01)

Neuroprotective effect of combination therapy of glatiramer acetate and epigallocatechin-3-gallate in neuroinflammation.
by: Katja Herges, et al.
Published: (2011-01-01)

Glatiramer acetate reduces the risk for experimental cerebral malaria: a pilot study
by: Helbok Raimund, et al.
Published: (2009-02-01)

A case of Disseminated Herpes Zoster in a patient with Multiple Sclerosis on Glatiramer acetate
by: C. Halasan, et al.
Published: (2020-01-01)

Efficacy, safety, and cost-effectiveness of glatiramer acetate in the treatment of relapsing–remitting multiple sclerosis
by: Aaron Boster, et al.
Published: (2011-09-01)

Glatiramer acetate increases phagocytic activity of human monocytes in vitro and in multiple sclerosis patients.
by: Refik Pul, et al.
Published: (2012-01-01)

Diagnosis of Exclusion: A Case Report of Probable Glatiramer Acetate-Induced Eosinophilic Myocarditis
by: Christopher J. Michaud, et al.
Published: (2014-01-01)

Glatiramer acetate 40 mg/ml: A review of the results of GALA and GLACIER clinical studies
by: N. Yu. Lashch, et al.
Published: (2016-07-01)

Validation of the procedure for determination of amino acids composition of glatiramer acetate by C-13 NMR spectroscopy
by: N. E. Kuz’Mina, et al.
Published: (2018-02-01)

Glatiramer acetate treatment normalizes deregulated microRNA expression in relapsing remitting multiple sclerosis.
by: Anne Waschbisch, et al.
Published: (2011-01-01)

The potential neuroprotective effects of weekly treatment with glatiramer acetate in diabetic patients after panretinal photocoagulation
by: Mitne S, et al.
Published: (2011-07-01)

CD4+/CD45RO+: A Potential Biomarker of the Clinical Response to Glatiramer Acetate
by: Martin Vališ, et al.
Published: (2019-05-01)

Clinical response to interferon beta and glatiramer acetate in multiple sclerosis patients: a Brazilian cohort
by: Valéria Coelho Santa Rita Pereira, et al.
Published: (2012-10-01)

Physicochemical, biological, functional and toxicological characterization of the European follow-on glatiramer acetate product as compared with Copaxone
by: S. Melamed-Gal, et al.
Published: (2018-09-01)

Enduring Clinical Value of Copaxone® (Glatiramer Acetate) in Multiple Sclerosis after 20 Years of Use
by: Daniel R. Wynn
Published: (2019-01-01)

Contrôle de la fonction régulatrice des lymphocytes B : effet du Glatiramer Acetate
by: Amrouche, Kahina
Published: (2015)

GLATIRAMER ACETATE IS A FIRST-LINE DUAL-ACTION DRUG FOR THE TREATMENT OF RELAPSING-REMITTING MULTIPLE SCLEROSIS
by: T. E. Shmidt
Published: (2016-12-01)

Brain Atrophy Rates for Stable Multiple Sclerosis Patients on Long-Term Fingolimod versus Glatiramer Acetate
by: Justin M. Honce, et al.
Published: (2020-09-01)

The immunomodulator glatiramer acetate influences spinal motoneuron plasticity during the course of multiple sclerosis in an animal model
by: K.B. Marques, et al.
Published: (2009-02-01)

Cannot write session to /tmp/vufind_sessions/sess_iqn3icamldd123tg0fo3dmfb91